Online Articles: Letters to the EdiorCOVID-19 Pandemic: Are We Back to Normal?Siesky, Brent PhD*; Harris, Alon MS, PhD, FARVO*; Verticchio Vercellin, Alice C. MD*,†,‡; Kalafatis, Nicholas BS§; Tsai, James C. MD, MBA∥Author Information *Department of Ophthalmology, Icahn School of Medicine at Mount Sinai Hospital ∥New York Eye and Ear Infirmary of Mount Sinai/Icahn School of Medicine at Mount Sinai †IRCCS—Fondazione Bietti, Rome ‡Department of Ophthalmology, University of Pavia, Pavia, Italy §Indiana University School of Medicine Indianapolis, IN Disclosure: A.H. would like to disclose that he received remuneration from Adom, Qlaris, and Luseed for serving as a consultant, and he serves on the board of Adom and Phileas Pharma. A.H. also holds an ownership interest in AdOM, Luseed, Oxymap, Phileas Pharma, and QuLent. All relationships listed above are pursuant to Icahn School of Medicine’s policy on outside activities. J.C.T. is a paid consultant for Eyenovia and ReNetX Bio. The contribution of the author A.C.V.V. was supported by Fondazione Roma and by the Italian Ministry of Health. The remaining authors declare no conflict of interest. Journal of Glaucoma: January 2021 - Volume 30 - Issue 1 - p e24-e25 doi: 10.1097/IJG.0000000000001699 Buy Metrics Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.